Biotech firm argenx SE is making strides in the development of therapies for autoimmune diseases across the globe, with a presence in the US, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the UK, and Italy. The firm's primary product candidate is efgartigimod, intended for the treatment of a range of conditions including immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy. The company is also pursuing development of other therapies such as ARGX-109 and ARGX-116, with emphasis on severe autoimmune conditions. Arguably most notable among the company's collaborations is its alliance with AbbVie S.À.R.L. and its strategic partnerships with Zai Lab Limited and LEO Pharma A/S. Founded in 2008, the firm is headquartered in the Dutch city of Amsterdam.